top of page


Enabling Cancer Precision Medicine and Research via Rapid and High-Quality Amplicon Sequencing

Cancer Statistics in India

  • One woman dies of cervical cancer every 8 minutes in India.

  • For every 2 women newly diagnosed with breast cancer, one woman dies of it in India.

  • Mortality due to tobacco use in India is estimated at upwards of 3500 persons every day.

  • Tobacco (smoked and smokeless) use accounted for 3,17,928 deaths (approx.) in men and women in 2018.

  • Estimated number of people living with the disease: around 2.25 million

  • Every year, new cancer patients registered: Over 11,57,294 lakh

  • Cancer-related deaths: 7,84,821

Enabling Cancer Precision Medicine and Research

  • next-generation sequencing (NGS) has been applied increasingly in cancer genomics research over the past decade. More recently, NGS has been adopted in clinical oncology to advance personalized treatment of cancer.

  • NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and provide molecular rationale for appropriate targeted therapy.

  • Hybrid capture and multiplex PCR are the two main targeted sequencing methods. Due to its sensitivity and workflow issue, hybrid capture-based sequencing can be less effective in dealing with samples containing either low amount of DNA or low frequency cancer mutations among normal DNA background.

  • Compared to hybrid capture, PCR amplicon sequencing could be a better choice mainly because it is highly sensitive, cost-effective and easy to implement in routine laboratory use.


Cancer may spread by directly invading the adjacent organs. Cancer cells often travel to other parts of the body by getting into the body’s blood stream/lymphatic vessels, where they grow and form new tumours. The process of cancer spread is called metastasis or invasion.

CleanPlex® DNA and RNA Amplicon Sequencing Technologies

Simple, Affordable Solution for Cancer Precision Medicine and Research

CleanPlex DNA Technology is a patented, scalable and ultra-sensitive multiplex PCR-based targeted DNA sequencing technology for next-generation sequencing (NGS). CleanPlex DNA workflow (Figure 1) starts with extracted DNA from fresh frozen tissue samples, FFPE tissues, cancer liquid biopsy samples, etc. The streamlined protocol can be completed in just 3 hours. Scientists or clinicians have the option to add molecular barcodes (unique molecular identifiers – UMIs) into amplicon libraries for more accurate detection of low frequency variants via CleanPlex UMI Technology.

CleanPlex RNA Technology is an ultra-high multiplex PCR-based target sequencing solution for RNA samples. CleanPlex RNA workflow (Figure 2) adds an additional proprietary reverse transcription step in front of CleanPlex DNA workflow so as to convert RNA to cDNA for downstream multiplex PCR amplification. By doing so, CleanPlex RNA inherits all the advantages and features of CleanPlex DNA technologies.

Figure 1. CleanPlex DNA Target Enrichment and Library Preparation Workflow

Figure 1. CleanPlex DNA Target Enrichment and Library Preparation Workflow

bottom of page